RxDoctor Payments Data

Mohamad Arja, MD

Internal Medicine · Lapeer, MINPI 1548299464

Payments from drug & device makers

$705in general payments, 2019–2025

Across 37 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$205
  • AbbVie$92
  • Lilly USA, LLC$64
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$63
  • Corcept Therapeutics$53
  • Pfizer$45
  • plus $183 from 8 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 70th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$225,106
Medicare patients
320
Services billed
4,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$200,197
OzempicSemaglutide81$103,105
JanuviaSitagliptin Phosphate102$95,711
JardianceEmpagliflozin87$93,105
TrulicityDulaglutide60$75,770
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,978
XareltoRivaroxaban21$16,603
MyrbetriqMirabegron22$15,524
Breo ElliptaFluticasone/Vilanterol27$13,168
Atorvastatin Calcium407$5,916
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$5,690
Levothyroxine Sodium507$5,687
PaxlovidNirmatrelvir/Ritonavir16$5,503
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,219
Nifedipine ErNifedipine91$4,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$45$205,700258 claims
Novo NordiskOzempic$205$103,10581 claims
Lilly USA, LLCTrulicity$64$75,77060 claims
GSKTrelegy Ellipta, Breo Ellipta$19$36,14653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Lapeer

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →